IL110045A - Pharmaceutical compositions containing oligopeptides for combating AIDS and ARC and for immune stimulation and certain such novel oligopeptides - Google Patents

Pharmaceutical compositions containing oligopeptides for combating AIDS and ARC and for immune stimulation and certain such novel oligopeptides

Info

Publication number
IL110045A
IL110045A IL11004594A IL11004594A IL110045A IL 110045 A IL110045 A IL 110045A IL 11004594 A IL11004594 A IL 11004594A IL 11004594 A IL11004594 A IL 11004594A IL 110045 A IL110045 A IL 110045A
Authority
IL
Israel
Prior art keywords
oligopeptides
arc
certain
pharmaceutical compositions
compositions containing
Prior art date
Application number
IL11004594A
Other languages
English (en)
Other versions
IL110045A0 (en
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of IL110045A0 publication Critical patent/IL110045A0/xx
Publication of IL110045A publication Critical patent/IL110045A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A61K38/105—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL11004594A 1993-06-18 1994-06-17 Pharmaceutical compositions containing oligopeptides for combating AIDS and ARC and for immune stimulation and certain such novel oligopeptides IL110045A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4320201A DE4320201A1 (de) 1993-06-18 1993-06-18 Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation

Publications (2)

Publication Number Publication Date
IL110045A0 IL110045A0 (en) 1994-10-07
IL110045A true IL110045A (en) 2000-06-01

Family

ID=6490614

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11004594A IL110045A (en) 1993-06-18 1994-06-17 Pharmaceutical compositions containing oligopeptides for combating AIDS and ARC and for immune stimulation and certain such novel oligopeptides

Country Status (24)

Country Link
US (1) US5985834A (da)
EP (1) EP0703786B1 (da)
JP (1) JPH08511784A (da)
KR (1) KR100352541B1 (da)
CN (1) CN1136915C (da)
AT (1) ATE213164T1 (da)
AU (1) AU688315B2 (da)
BR (1) BR9406893A (da)
CZ (1) CZ285997B6 (da)
DE (2) DE4320201A1 (da)
DK (1) DK0703786T3 (da)
ES (1) ES2172533T3 (da)
FI (1) FI113008B (da)
HU (1) HUT73673A (da)
IL (1) IL110045A (da)
NO (1) NO320945B1 (da)
PL (1) PL175580B1 (da)
PT (1) PT703786E (da)
RU (1) RU2154492C2 (da)
SG (1) SG52240A1 (da)
TW (1) TW370532B (da)
UA (1) UA41938C2 (da)
WO (1) WO1995000168A1 (da)
ZA (1) ZA944347B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
US8962558B2 (en) 1997-07-04 2015-02-24 Johannes C. van Groeninghen Methods for reducing GnRH-positive tumor cell proliferation using the GnRH antagonist IN3
DE19728737C1 (de) * 1997-07-04 1999-02-11 Johannes Christian Groeninghen Verfahren zur Erkennung und Bestimmung von GnRH-Rezeptoren und die Verwendung von GnRH-Agonisten und GnRH-Antagonisten zur Behandlung eines Tumors ausgehend vom Hirn und/oder Nervensystem und/oder den Hirnhäuten
CN1443195A (zh) * 2000-03-14 2003-09-17 赞塔里斯股份公司 新型lhrh拮抗剂,其制备方法和药物用途
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
US20040138138A1 (en) * 2001-08-02 2004-07-15 Jurgen Engel Use of LHRH-antagonists in doses that do not cause castration for the improvement of T-cell mediated immunity
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
RU2314818C1 (ru) * 2006-03-06 2008-01-20 Институт биоорганической химии РАН им. М.М. Шемякина и Ю.А. Овчинникова (ИБХ) Средство, обладающее ингибирующей способностью по отношению к обратной транскриптазе вируса иммунодефицита человека
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
WO2010004273A1 (en) 2008-07-07 2010-01-14 Oxford Nanopore Technologies Limited Base-detecting pore
EP2307540B1 (en) 2008-07-07 2017-04-19 Oxford Nanopore Technologies Limited Enzyme-pore constructs
GB0820927D0 (en) 2008-11-14 2008-12-24 Isis Innovation Method
WO2010086622A1 (en) 2009-01-30 2010-08-05 Oxford Nanopore Technologies Limited Adaptors for nucleic acid constructs in transmembrane sequencing
US20120100530A1 (en) * 2009-01-30 2012-04-26 Oxford Nanopore Technologies Limited Enzyme mutant
GB0905140D0 (en) 2009-03-25 2009-05-06 Isis Innovation Method
EP2673638B1 (en) 2011-02-11 2019-10-30 Oxford Nanopore Technologies Limited Mutant pores
IN2014DN00221A (da) 2011-07-25 2015-06-05 Oxford Nanopore Tech Ltd
JP6271505B2 (ja) 2012-04-10 2018-01-31 オックスフォード ナノポール テクノロジーズ リミテッド 変異体ライセニンポア
WO2014013259A1 (en) 2012-07-19 2014-01-23 Oxford Nanopore Technologies Limited Ssb method
GB201314695D0 (en) 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
BR112015021788B1 (pt) 2013-03-08 2023-02-28 Oxford Nanopore Technologies Plc Métodos para mover uma ou mais helicases imobilizadas, para controlar o movimento de um polinucleotídeo alvo, para caracterizar um polinucleotídeo alvo e para controlar o carregamento de uma ou mais helicases em um polinucleotídeo alvo, uso de um poro de transmembrana e de um potencial aplicado e de um ou mais espaçadores, complexo, e, kit
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
EP3137627B1 (en) 2014-05-02 2025-07-30 Oxford Nanopore Technologies plc Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
KR20170042794A (ko) 2014-09-01 2017-04-19 브이아이비 브이지더블유 돌연변이체 csgg 포어
WO2016055778A1 (en) 2014-10-07 2016-04-14 Oxford Nanopore Technologies Limited Mutant pores
GB201418159D0 (en) 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
CN105837674A (zh) * 2016-03-08 2016-08-10 无限极（中国）有限公司 一种东方铃蟾多肽及其制备方法与应用
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677193A (en) * 1985-02-22 1987-06-30 The Salk Institute For Biological Studies Peptides containing an aliphatic-aromatic ketone side chain
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
AU618029B2 (en) * 1987-11-02 1991-12-12 Imperial Chemical Industries Plc Polypeptide compounds
WO1989009229A1 (en) * 1988-03-31 1989-10-05 Immunobiology Research Institute, Inc. Treatment of hiv viremic patients with thymopentin
JP2919889B2 (ja) * 1988-10-14 1999-07-19 アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド 治療用ペプチド
US5089508A (en) * 1990-09-04 1992-02-18 Burzynski Stanislaw R Methods for treating aids
US5087625A (en) * 1990-10-19 1992-02-11 Boehringer Ingelheim Pharmaceuticals, Inc. Pyridodiazepines and their use in the prevention or treatment of HIV infection
US5244883A (en) * 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
ES2117045T3 (es) * 1990-12-21 1998-08-01 Curative Tech Inc Peptidos angiogenicos.
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.

Also Published As

Publication number Publication date
DK0703786T3 (da) 2002-05-27
CN1125400A (zh) 1996-06-26
DE4320201A1 (de) 1995-01-12
FI956014L (fi) 1995-12-14
PL312219A1 (en) 1996-04-01
JPH08511784A (ja) 1996-12-10
UA41938C2 (uk) 2001-10-15
US5985834A (en) 1999-11-16
IL110045A0 (en) 1994-10-07
CZ285997B6 (cs) 1999-12-15
ES2172533T3 (es) 2002-10-01
NO954996D0 (no) 1995-12-08
HU9503605D0 (en) 1996-02-28
TW370532B (en) 1999-09-21
RU2154492C2 (ru) 2000-08-20
NO954996L (no) 1995-12-08
SG52240A1 (en) 1998-09-28
BR9406893A (pt) 1996-09-10
KR960703015A (ko) 1996-06-19
PT703786E (pt) 2002-07-31
PL175580B1 (pl) 1999-01-29
KR100352541B1 (ko) 2002-12-26
NO320945B1 (no) 2006-02-20
ZA944347B (en) 1995-02-15
HUT73673A (en) 1996-09-30
FI113008B (fi) 2004-02-27
EP0703786B1 (de) 2002-02-13
EP0703786A1 (de) 1996-04-03
AU688315B2 (en) 1998-03-12
CN1136915C (zh) 2004-02-04
WO1995000168A1 (de) 1995-01-05
DE59410052D1 (de) 2002-03-21
ATE213164T1 (de) 2002-02-15
FI956014A0 (fi) 1995-12-14
AU6564794A (en) 1995-01-17
CZ308995A3 (en) 1996-03-13

Similar Documents

Publication Publication Date Title
IL110045A0 (en) Pharmaceutical compositions containing oligopeptides combating aids and arc and for immune stimulation and certain such novel oligopeptides
IL111734A0 (en) Compositions for the preparation of in vivo therapeutic products
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
GEP20053473B (en) High Potency Dihydroergotamine Compositions
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
IL136503A0 (en) Adamantane derivatives
IL136369A0 (en) Adamantane derivatives
MY125978A (en) Admantane derivatives
GR3022510T3 (en) Lyospheres comprising gonadotropin
AP9801392A0 (en) Concentrated antibody preparation.
GEP20063741B (en) Nonaryl-Heterocyclic NMDA/NR2B Antagonists
CA2153340A1 (fr) Application du riluzole dans le traitement de la maladie de parkinson et des syndromes parkinsoniens
AU1890295A (en) Piperidines and pyrrolidines
EP0663835A1 (en) USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS.
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
AU9731198A (en) Histogranin peptide and their analgesic use
PL315127A1 (en) Deuterised biologically active substances for percutaneous administration
AU3808795A (en) Water-soluble derivatives of epipodophyllotoxin, process for their preparation, their use as medicinal product and their intended use in anticancer treatments
MXPA04001912A (es) Aminobenzofenonas novedosas.
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
GEP20043377B (en) Pharmaceutical Complex
GB9505082D0 (en) Medicament
AU7941294A (en) Composition for the treatment or prevention of herpes
AU2811400A (en) Stable formulation containing fumagillin

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HP Change in proprietorship
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees